Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


LentiGlobin Hogs The Limelight At CHMP’s First Amsterdam Meeting

Executive Summary

An opinion on whether bluebird bio’s transfusion-dependent β-thalassemia gene therapy, LentiGlobin, should be granted an EU marketing authorization is due this week as the EMA’s key scientific committee, the CHMP, meets for the first time in Amsterdam.


Related Content

EU Hat Trick For Bluebird’s Beta-Thalassemia Gene Therapy
Goodbye To All That: EMA Leaves London After 24 years


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts